Home

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

Antibodies

Chemical Structure Cat. No. Product Name CAS No.
Single chain des-B30-insulin Chemical Structure
BCP39490 Single chain des-B30-insulin 39416-73-4
Insulin Aspart Chemical Structure
BCP39489 Insulin Aspart 116094-23-6
Brolucizumab Chemical Structure
BCP39189 Brolucizumab 1531589-13-5
Brolucizumab is a humanized single-chain antibody.
Edrecolomab Chemical Structure
BCP36542 Edrecolomab 156586-89-9
Edrecolomab is a mouse-derived monoclonal antibody targeting the cell-surface glycoprotein EpCAM (17-1A), which is expressed on epithelial tissues and on various carcinomas.
Trastuzumab deruxtecan Chemical Structure
BCP36537 Trastuzumab deruxtecan 1826843-81-5
Trastuzumab deruxtecan is an antibody-drug conjugate that includes a human epidermal growth factor receptor 2 (HER2)-directed antibody trastuzumab and a topoisomerase I inhibitor conjugate deruxtecan (a derivative of exatecan).
Alirocumab Chemical Structure
BCP25199 Alirocumab 1245916-14-6
Alirocumab is a human monoclonal antibody to PCSK9 (proprotein convertase subtilisin/kexin type 9), a circulating protein that modulates the activity of the LDL cholesterol receptor in the liver. The monoclonal antibody lowers serum LDL cholesterol and is used to treat severe hypercholesterolemia. Alirocumab therapy has been associated with a low rate of serum aminotransferase elevations and has yet to be linked to instances of clinically apparent acute liver injury.
Tislelizumab Chemical Structure
BCP35899 Tislelizumab Tislelizumab
Tislelizumab (BGB-A317) is a humanized monoclonal antibody directed against PD-1. It prevents PD-1 from binding to the ligands PD-L1 and PD-L2 (hence it is a checkpoint inhibitor). It is being investigated as a treatment for advanced solid tumors.
Ramucirumab Chemical Structure
BCP26258 Ramucirumab 947687-13-0
Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D.
Vedolizumab Chemical Structure
BCP26256 Vedolizumab 943609-66-3
Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
Ozanezumab Chemical Structure
BCP23507 Ozanezumab 1310680-64-8
Ozanezumab is a monoclonal antibody.
123下一页末页共 68 条记录 1 / 7 页 
0086-13720134139